Several biomarkers, such as the tumor mutational burden, PD‐L1 expression of tumor cells, or scores like the combined positive score have been suggested to be able to better select patients and to improve the prediction of individualized ICI treatment efficacy.13, 14. This evidence concerns the gene CD274 and neoplasm.